Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (24)

Justin J Wilkins (1,2), Radojka M Savic (2), Mats O Karlsson (2), Grant Langdon (1), Helen McIlleron (1), Goonaseelan (Colin) Pillai (3), Peter J Smith (1), Ulrika SH Simonsson (2,4)

A flexible approach to modeling variable absorption in the context of repeated dosing: illustrated with rifampicin

Claudio Cobelli

Models of Glucose Metabolism and Control in Diabetes

Robert J. Bauer

Advanced Population Analysis Features in the S-ADAPT/MCPEM Program

Benoit You (1,2) , Paul Perrin (1,2), Philippe Paparel (1,2), Gilles Freyer (1,2), Olivier Colomban (1) Brigitte Tranchand (1,3), Pascal Girard (1)

Kinetic models of PSA decrease after surgery in prostate tumor diseases as a help for clinician interpretation

Joakim Nyberg, Mats O Karlsson, Andrew Hooker

Sequential versus simultaneous optimal experimental design on dose and sample times

Tim Sheiner

Planning To Communicate

JF Standing (1,2), RF Howard (1,3), A Johnston (4), I Savage (2), ICK Wong (1,2,3)

Developmental Pharmacokinetics of Diclofenac for Acute Pain

Kim Stuyckens, Stefaan Rossenu, Peter King, Janine Arts, Juan Jose Perez-Ruixo.

Modeling Drug Effects and Resistance Development on Tumor Growth Dynamics

Francesca Del Bene, Massimiliano Germani, Maurizio Rocchetti, Alex De Giorgio-Miller, Nick Pullen, Peter Bungay, Chris Kohl & Piet van der Graaf

A population PK-PD method for categorical data analysis of progesterone antagonist activity in the rabbit McPhail’s model

Jeroen Schaap

Interspecies Population Modeling Of Pharmacokinetic Data Available At The End Of Drug Discovery

Sau Yan Amy Cheung (1), James W. T. Yates (2), Oneeb Majid (3), Leon Aarons (4)

Identifiability Analysis and Parameter List Reduction of a Nonlinear Cardiovascular PKPD Model

Strougo, A(1), Elassaiss-Schaap, J(2), de Greef, HJMM(2), Drenth, H(1)

Mechanism-based model of the effect of co-administration of exogenous testosterone and progestogens on the hypothalamic-pituitary-gonodal axis in men

F. Mentré (1), S. Duffull (2), I. Gueorguieva (3), A. Hooker (4), S. Leonov (5), K. Ogungbenro (6), S. Retout (1)

Software for optimal design in population pharmacokinetics and pharmacodynamics: a comparison

Radojka M. Savic and Mats O. Karlsson

Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics and Estimation: Problems and Solutions

E.H. Cox (1)(3), N.H. Prins (1), G. D’Souza (2) & L. McFadyen (2)

Integrated Modeling & Simulation of Clinical Response and Drop-out of D2 receptor agonists in Patients with Early Parkinson’s Disease.

C. Dansirikul, M.O. Karlsson

Insulin secretion and hepatic extraction during euglycemic clamp study: modelling of insulin and C-peptide data

M. Lavielle (1,2), H. Mesa (3,2), F. Mentré (4,5)

The SAEM algorithm and its implementation in MONOLIX 2.1

F. Nekka, J. Li and F. Fenneteau

What Additional Information Can we Retrieve When Compliance is Accounted For? An explicit Compliance-Pharmacokinetic Formalism

Kristin E. Karlsson(1), Justin Wilkins(1,3), Mats O. Karlsson(1) and E. Niclas Jonsson(1,2)

Modelling of disease progression in acute stroke by simultaneously using the NIH stroke scale, the Scandinavian stroke scale and the Barthel index

Stefano Zamuner, Roberto Gomeni

Optimal Design to Estimate the Time Varying Receptor Occupancy Relationship in a PET Experiment

Teun Post(1), Tomoo Funaki(2), Hiromi Maune(2), Henk-Jan Drenth(1)

Circadian rhythm in pharmacodynamics and its influence on the identification of treatment effects

Philippe Jacqmin (1), Lynn McFadyen (2) and Janet R. Wade (1)

Basic PK/PD principles of proliferative and circular systems

Brendel K1,2, Comets E1, Laffont C.M2, Mentré F1,3.

Normalized Prediction Distribution Error for the Evaluation of Nonlinear Mixed-Models

Dartois C, Looby M, He H, Steimer J-L, and Pillai G.

Impact of handling missing PK data on PD estimation – explicit modeling of BLQ data in WinBUGS® reduced bias in the PD predictions – a preclinical example.